Evidence map›Paper›PMID 38758363›Full record

Trial reportEuropean journal of nutrition2024

N-3 PUFA supplementation alleviates anxiety symptoms by manipulating erythrocyte fatty acid levels in depression.

Lu Wang, Ting Liu, Jimin Guo, Tingyu Zhao, Hui Tang, Feifei Wang, Fang Dong, Jindong Chen, Mimi Tang

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Evaluating the causal effects of circulating metabolites on major depression disorder.European archives of psychiatry and clinical neuroscience · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lu Wang *The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, 100088, China.
Ting Liu *Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Jimin GuoCollege of Materials Sciences and Engineering, Beijing University of Chemical Technology, Beijing, 100029, China.
Tingyu ZhaoDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Hui TangDepartment of Psychiatry, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, and China National Technology Institute on Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Feifei WangThe National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, 100088, China.
Fang DongThe National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders and Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing, 100088, China.
Jindong ChenDepartment of Psychiatry, National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, and China National Technology Institute on Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Mimi TangDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China. tangmimi1989@163.com.

Funding

Hospital Pharmacy Innovation Project for the youth established by Chinese Pharmaceutical Association and Servier (Tianjin) Pharmaceutical Co. Ltd. CPA-B04-ZC-2024-001National Natural Science Foundation of China 81803233National Natural Science Foundation of China 82301686Natural Science Foundation of Changsha City kq2208387Natural Science Foundation of Hunan Province 2023JJ30938
6 · The paper itself

Abstract

purposeMajor depressive disorder (MDD) is frequently accompanied by the symptoms of clinical anxiety. Since our previous research has found that n-3 PUFA supplementation alleviates anxiety in MDD, this study was aimed to further explore whether n-3 PUFA supplementation improves anxiety symptoms in depression by directly manipulating fatty acid levels.

methodsA secondary analysis of biomarker data (erythrocyte fatty acid composition) collected as part of the randomized clinical trial which investigated the adjunctive effect of n-3 PUFAs was conducted on 72 venlafaxine-treated outpatients with first-diagnosed, drug-naïve depression. All participants with longitudinal biomarker data were included in the association analysis to determine how n-3 PUFA supplementation influences fatty acid composition and alleviates anxiety symptoms in depression.

resultsDecreases of the C20:3n6 were found in all participants at both follow-up time points (χ

conclusionThese data suggest that the anxiolytic effect exerted by n-3 PUFAs in first-diagnosed, drug-naïve depression is manipulated by erythrocyte fatty acid levels. Saturated fatty acid levels have an important role in predicting the severity of anxiety symptoms.

Indexed as

AnxietyDietary SupplementsErythrocytesFatty AcidsFatty Acids, Omega-3Major Depressive DisorderAdultBiomarkersDepressionFemaleHumansMaleMiddle AgedBiomarkersFatty AcidsFatty Acids, Omega-3AnxietyDepressionFatty acidsN-3 PUFAs

Identifiers

PMID38758363

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.